A treatment of pediatric hyperphosphatemia being developed by Ardelyx was granted FDA orphan status, according to a post to the agency’s website.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ARDX:
- XPHOZAH® (tenapanor) Granted Orphan Drug Designation by U.S. FDA for the Treatment of Pediatric Hyperphosphatemia
- Ardelyx Announces Departure of Board Member
- Ardelyx to Participate at the Jefferies London Healthcare Conference
- Ardelyx announces XPHOZAH is now available in the U.S.
- Ardelyx Shares Positive Data from Studies of XPHOZAH® (tenapanor), a First-in-Class Phosphate Absorption Inhibitor, at ASN Kidney Week 2023